BriOri Biotech

BriOri Biotech is a clinical-stage biotechnology company dedicated to the development of novel topical medications for the treatment of osteoarthritis and other pain-related conditions. The company's lead product candidate, BO-101, is a proprietary topical formulation of the non-steroidal anti-inflammatory drug (NSAID) diclofenac. BriOri's technology is designed to enhance skin penetration and local tissue concentration while minimizing systemic absorption, thereby reducing the risk of gastrointestinal and cardiovascular side effects. The company is currently focused on advancing BO-101 through Phase 2 clinical development to provide a safer and more effective alternative to oral pain medications.